Non Hodgkin Lymphoma (NHL) Market Report 2026

Non Hodgkin Lymphoma (NHL) Market Overview

• Non Hodgkin Lymphoma (NHL) market size has reached to $10.86 billion in 2025 • Expected to grow to $16.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: High Prevalence Of Non-Hodgkin Lymphoma Fuels Market Growth • Market Trend: Advancements In Non-Hodgkin Lymphoma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non Hodgkin Lymphoma (NHL) Market?

Non-Hodgkin lymphoma is a cancer of the lymphatic system characterized by the abnormal growth of white blood cells. It is a form of cancer that develops in the immune system component of the body's lymphatic system, which is responsible for battling infection. The main types of non-Hodgkin lymphoma (NHL) are B-cell lymphoma and T-cell lymphoma. B-cell lymphoma refers to a group of cancer that originate from abnormal B lymphocytes in the immune system. Non-Hodgkin lymphoma treatment for B-cell lymphomas typically involves a combination of therapies, such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplant. The various types of treatments are involved, including surgery, stem cell transplant, chemotherapy, immunotherapy, targeted therapy, and radiation therapy, which can be administered through various routes, including oral, parenteral, and others. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and are used by various end-users, including hospitals, homecare facilities, specialty centers, and others.

What Is The Non Hodgkin Lymphoma (NHL) Market Growth Forecast?

The non hodgkin lymphoma (nhl) market size is expected to see strong growth in the next few years. It will grow to $16.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to pipeline growth of targeted therapies, increasing approvals of biologics, rising adoption of personalized medicine, expanding access in emerging markets, growth in stem cell transplant procedures. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy, increasing use of combination treatment regimens, growing focus on early and accurate diagnosis, expansion of personalized treatment protocols, shift toward outpatient and home-based care models.

Global Non Hodgkin Lymphoma (NHL) Market Segmentation

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma 2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy 3) By Route of Administration: Oral, Parenteral, Other Routes of Administration 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users Subsegments: 1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma 2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Is The Driver Of The Non Hodgkin Lymphoma (NHL) Market?

The high prevalence of non-Hodgkin lymphoma is expected to propel the growth of the non-Hodgkin lymphoma market going forward. It is a cancer that develops in the lymphatic system, which is part of your immune system. The prevalence of non-Hodgkin lymphoma refers to the number of individuals in a population who are currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment helps improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer health organization, non-Hodgkin lymphoma accounts for 4% of all cancers, and in 2023, it will affect around 80,550 Americans, including 44,880 males and 35,670 females. It also estimates that 20,180 people will die in 2023 because of non-Hodgkin lymphoma. Therefore, the high prevalence of non-Hodgkin lymphoma is driving the non-Hodgkin lymphoma market.

Key Players In The Global Non Hodgkin Lymphoma (NHL) Market

Major companies operating in the non hodgkin lymphoma (nhl) market are Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Global Non Hodgkin Lymphoma (NHL) Market Trends and Insights

Major companies operating in the non-Hodgkin lymphoma market are increasing their focus on introducing advanced immunotherapies, such as Epcoritamab-bysp (EPKINLY), to gain a competitive edge in the market. Epcoritamab-bysp (EPKINLY) is an investigational subcutaneous immunotherapy designed to target CD20-expressing B-cell malignancies, showing promising results in clinical trials, particularly in relapsed or refractory B-cell non-Hodgkin lymphoma. For instance, in November 2023, AbbVie Inc., a US-based pharmaceutical company, received a breakthrough therapy designation (BTD) from the United States Food and Drug Administration for Epcoritamab-bysp (EPKINLY). The approval was granted for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more therapies. Additionally, the European Medicines Agency (EMA) has validated a Type II application for epcoritamab (TEPKINLY) for the same indication. These updates were supported by previously announced results from the Phase 1/2 EPCORE NHL-1 clinical trial. The trial evaluated the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

What Are Latest Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market?

In May 2023, Janssen Biotech Inc., a U.S.-based developer of innovative pharmaceutical therapies, entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group for $245 million upfront. Through this agreement, Janssen aims to expand its oncology portfolio and accelerate the development of next-generation chimeric antigen receptor T-cell therapies targeting CD19 and CD20 for relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma, a major subtype of non-Hodgkin lymphoma. Cellular Biomedicine Group is a US-based biotechnology company specializing in advanced cell therapies, including autologous CAR-T candidates with demonstrated early-phase clinical activity in non-Hodgkin lymphoma.

Regional Insights

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non Hodgkin Lymphoma (NHL) Market?

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non Hodgkin Lymphoma (NHL) Market Report 2026?

The non hodgkin lymphoma (nhl) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non hodgkin lymphoma (nhl) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.